Nuvectis Pharma, Inc. (NVCT) - Quarterly EPS earnings growth

Official company branding of Nuvectis Pharma (NVCT)

Nuvectis Pharma, Inc. (NVCT) focuses on independent testing of its own molecules without external partnerships. Experienced management rapidly allocates capital to complete clinical stages. Tracking the shift in quarterly EPS levels on GURU.Markets, we note that the value -134.70 reflects the current figure. Nuvectis Pharma, Inc. (NVCT) attracts leading scientists with ambitious R&D objectives, guaranteeing them high autonomy and lucrative stock option programs.

Nuvectis Pharma (NVCT) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/17/2026

Analytical breakdowns for Nuvectis Pharma, Inc.

- market value and analyst target forecast:
Fundamental company analysis:nuvectis.com, NVCT
Manufactured product of Nuvectis Pharma, Inc

Nuvectis Pharma, Inc. (NVCT) focuses on developing targeted therapies for the treatment of rare oncological diseases. This indicator measures the percentage change in net earnings per share compared to the same period last year. Growth in this metric confirms the effectiveness of investments in science and the future commercialization of drugs. A positive trend signals an increase in the cost of capital. By analyzing the quarterly growth in earnings per share, an investor can determine the optimal entry point, avoiding purchases at local peaks.

Analysis of competing companies

Incyte Corporation (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HUTCHMED Corp|NUVB (nuvationbio.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months dayonebio.com (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Corp (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Inc. IMAB|Fennec - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months coherus.com|CRBP: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Cardiff Oncology, Inc. CRDF|Year-over-year net earnings per share growth for the last 12 months BYSI|Earnings per share growth in annualized terms for the last twelve months BioAtla BCAB|Year-over-year net earnings per share growth for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Year-over-year earnings per one share growth for the last 12 months|Cellectar Biosciences - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (aprea.com)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion (SLXN)|Year-over-year earnings per share growth for the last twelve months nucana.com|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth G1 Therapeutics Inc. (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Therapeutics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Portage Biotech Inc